Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins and clotting factors for transfusion support in patients with hematologic disease
Date
2020Author
Nair, Prajeeda M.
Rendo, Matthew J.
Reddoch-Cardenas, Kristin M.
Burris, Jason K.
Meledeo, Michael A.
Cap, Andrew P.
Metadata
Show full item record
Documentos PDF
Imagenes y Videos
Abstract
Hematologic diseases include a broad range of acquired and congenital disorders, spanning
dysfunction of the bone marrow, red blood cells, leukocytes and platelets. The plasma proteins of the
coagulation system, the complement system as well as the immunoglobins can also be affected. Finally,
hematologic diseases affect the vascular endothelium from which blood arises during embryogenesis, and
with which blood constantly interacts.
Unsurprisingly, a common component of treatment strategies for patients with hematologic disease
involves replacement or enrichment of missing, dysfunctional or consumed constituents of blood through
transfusion. This review will focus on the recent advances in the use of plasma and its derivatives,
cryoprecipitate, immunoglobin preparations and individual clotting factors for patients with acquired and
congenital hematologic disorders.
Palabras clave
Plasma; Hematologic disease; Transfusion; COVID-19Link to resource
https://doi.org/10.1053/j.seminhematol.2020.07.006Collections
Estadísticas Google Analytics
Comments
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.